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Efficacy data were computed from all randomized trials (RT) that guided on-label
uses of bevacizumab (K-Ras mutated), panitumumab and cetuximab. Non- signif-
icant outcomes and toxicity as predictor of efficacy were excluded. Prices for drugs
in Spain were assumed to represent the best-value for each drug including all
possibilities to reduce pharmacy costs. For 1st line, median duration of therapy
reported by RT was used to calculate the final budget. 70kg and 1.7 m were used as
reference for patient dose calculations. RESULTS: We simulated 3 main scenarios
based on the possibilities of therapy for K-Ras wild type (wt) patients assuming that
all patients harboring a K-Ras mutated tumor received bevacizumab based chemo-
therapy. So, in scenario A K-Ras wt patients received weekly cetuximab combined
with FOLFOX, ORR reaches 54% and global cost per RR sums €20,026. Scenario B:
administering panitumumab-FOLFOX yields 51% ORR and € 19,861 per RR. Scenario
C: cetuximab biweekly combined with FOLFOX yields 54% and €19,726. ICER for
scenario A vs B is estimated at € 22,835 per additional response. ICER for scenario C
vs B is estimated at € 968 per additional response. CONCLUSIONS: First-line oxali-
patin combinations of cetuximab for wt and bevacizumab for mutated patients
optimize response rate rather than panitumumab and bevacizumab schedules.
Efficiency of this therapeutic approach could be improved with biweekly cetux-
imab administration. Marginal cost differences between cetuximab and panitu-
mumab therapies are exceeded by efficacy gap as measured by response rates in
RT.
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OBJECTIVES: An analysis recently evaluated hematologic responses among 126
Iraqi Ph CML-CP patients who were switched from Glivec (the beta crystalline
form of imatinib mesylate [IM]), to an alpha crystalline form, generic copy of ima-
tinib (IMgc). At the time of IMgc switch, patients had received IM for 50 months and
were at least in complete hematologic response (CHR). Three months post-switch,
18 (14%) and 4 (3%) patients progressed to accelerated phase (AP) and blast crisis
(BC), respectively. Six months post-switch, an additional 20 (16%) lost hematologic
response. A previously-published CML Markov model was adapted to compare over
50 years the projected life-years (LYs), progression-free life-years (PFLY), and qual-
ity-adjusted life-years (QALYs) of IM patients switched vs. not switched to IMgc.
METHODS: Patients entered the model after 50 months of IM therapy. At that time,
based on the IRIS trial results, patients were assumed to be distributed in CHR
(4.7%), partial (6.5%) and complete (88.9%) cytogenetic response. Patients remain-
ing on IM transitioned within these 3 responses levels and no hematologic re-
sponse, AP, BC, and death according to the original model probabilities. For pa-
tients switched to IMgc, transition rates were based exclusively on rates observed
in the Iraqi study (Scenario 1) or on the Iraqi study for the first 6 months and
thereafter on the original model (Scenario 2). Utilities were from the original model.
RESULTS: Patients remaining on IM were predicted to experience 15.71 LYs, 14.51
PFLYs, and 13.44 QALYs. Corresponding numbers for patients switched to IMgc
were 2.42 LYs, 1.13 PFLYs, 1.39 QALYs (in Scenario 1) and 11.44 LYs, 10.19 PFLYs, and
9.57 QALYs (in Scenario 2). Results were also sensitive to response distribution at
model entry. CONCLUSIONS: Switching from IM to an IMgc that does not have the
same properties may result in substantial loss of LYs, PFLYs, and QALYs.
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OBJECTIVES: Crizotinib, a tyrosine kinase anaplastic lymphoma kinase (ALK) in-
hibitor, represents a therapeutic alternative to patients with locally advanced or
metastatic non-small cell lung cancer (NSCLC) that are ALK. This study aimed to
estimate the cost-effectiveness of crizotinib in the treatment of this group of pa-
tients compared to currently available chemotherapy schemes:
gemcitabinecisplatin (GC), pemetrexedcisplatin (PC) and docetaxelcisplatin
(DC), from the Mexican public payer’s perspective. METHODS: A mutually exclu-
sive, four-state Markov model was developed: stable without progression, stable
with response to treatment, disease progression and death (monthly transitions,
six-year timeframe, 5% discount rate). The model assess life-years gained and
direct medical costs (pre-treatment, drugs costs, drug administration, monitoring
and adverse event management), per each treatment (basecase GC), in terms of
ICER. Effectiveness data was extracted from published literature. Drug costs and
medical resources were extracted from Instituto Mexicano del Seguro Social data-
base. Crizotinib’s cost were provided by manufacturer (not listed yet in Mexican
formulary) and are expressed in 2012 US$. Univariate sensitivity analyses regard-
ing monthly acquisition cost and clinical efficacy of crizotinib were performed.
RESULTS: Crizotinib was the most effective alternative with 3.02 life-years gained,
compared with 1.55, 1.74 and 1.34 for GC, PC and DC, respectively. The cost of GC
was $15,792.3, while the incremental cost for PC, DC and crizotinib were $10,787.4,
$13,171 and $61,895.3, respectively. DC was dominated, while ICER for PC and cr-
izotinib were $56,775.9 and $42,105.6, respectively, being crizotinib a cost-effective
alternative. Results were sensible to changes in acquisition cost of crizotinib and
less sensible to changes in the probabilities of death and disease progression with
crizotinib. CONCLUSIONS: From the Mexican public payer’s perspective, crizotinib
would represent an opportunity for both, this group of patients, and health care
institutions to achieve better clinical results than GC, PC and DC, as well as minor
cost regarding PC.
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OBJECTIVES: Breast-cancer is the most frequent malignancy amongst women in
Europe and therefore represents a major public-health problem. The purpose of
this analysis was to estimate the cost-effectiveness of AT (doxorubicin, docetaxel)
compared with AC (doxorubicin, cyclophosphamide), CMF (cyclophosphamide,
methotrexat, 5-fluoruracil) and FEC (5-fluoruracil, epirubicin, cyclophosphamide)
administered as adjuvant therapy to women with node-positive breast-cancer
across four European countries (Spain, Italy, Germany and Belgium). METHODS:
We developed a multi-country Markov-model to simulate the long-term conse-
quences from initiation of adjuvant chemotherapy over 10 years. The model sim-
ulates the incidence of complications during chemotherapy (febrile neutropenia,
chemotherapy-induced nausea/vomiting, dose-reduction, dose-delay, grade 3/4
adverse events) and long-term consequences like local or distant-relapse, acute
myelogenous leukemia (AML), chronic heart failure and death. Monte-Carlo-sim-
ulation accounted for uncertainty. The model includes twelve health-states. Prob-
abilities were derived from clinical and epidemiological studies; direct costs (2011)
from published sources from the payer’s perspective. QALYs, life-years (LYs) and
costs were discounted at 5% p.a. RESULTS: Over a 10-year timeframe, costs asso-
ciated with AC are 13,266€, 14,826€, 15,699€ and 16,558€ for Spain, Italy, Germany
and Belgium, respectively. AC is associated with 5.85 QALYs (6.49 LYs). Costs for AT
amount to 15,362€ (Spain), 19,004€ (Italy), 19,768€ (Germany) and 20,625€ (Belgium)
and AT delivers a similar benefit to AC: 5.85 QALYs (6.50 LYs). The resulting oppor-
tunities for cost-savings with AC vs. AT are between 2,096€ (Spain) and 4,178€
(Italy). Costs associated with CMF are 14,145€ (Spain), 15,609€ (Italy), 16,411€ (Ger-
many) and 16,924€ (Belgium); 5.8 QALYs (6.4 LYs) are gained. AC dominates CMF.
FEC associated total costs are 15,138€ (Spain), 15,652€ (Italy), 17,431€ (Germany) and
17,492€ (Belgium). QALYs are 6.03 (6.81 LYs). FEC dominates AT in all four countries.
CONCLUSIONS: Cyclophosphamide-based regimens (FEC, AC and CMF) demon-
strate a better performance from cost-effectiveness perspective vs. AT in the four
European countries.
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OBJECTIVES: Renal cell carcinoma (RCC) accounts for approximately 2% of all can-
cers worldwide. Many patients present with advanced or unresectable disease, and
up to 30% of patients treated by nephrectomy for localized disease will relapse.
Improved care for patients with metastatic RCC (mRCC), including targeted thera-
pies have improved prognosis but have also increased drug costs. In this study, we
set out to study costs and outcomes in mRCC treatment using national registries
comprising all patients diagnosed with RCC in Sweden. METHODS: Two cohorts of
patients diagnosed with mRCC 2002-2005 and 2006-2008, representing patients
diagnosed pre- and post-TKI introduction respectively, were identified in the na-
tional Swedish Cancer Registry. A pre-defined algorithm was used to determine the
presence of mRCC. Through record linkage with the national registries for drug
prescriptions, hospital care, and causes of death, data on resource utilization and
survival was obtained. The Kaplan-Meier method was used to estimate survival,
using an exponential model to calculate the mean for 4.5 years - beyond the end of
the observation period. Costs were estimated in 2010 SEK (1 SEK  USD ($) 0.14),
using the Lin method to account for censoring. Sensitivity analysis was done to
better incorporate the cost of hospital dispensed drugs. RESULTS: Patients diag-
nosed post-TKI introduction (n1,217) had longer survival (median 1.08 compared
to 0.79 years, restricted mean 1.73 compared to 1.55, both p  0.001) compared to
patients diagnosed pre-TKI introduction (n1,536). Costs were higher for patients
more recently diagnosed: $52,601 versus $40,970. Pharmaceutical costs were
$12,418 higher in the post period but where slightly offset by lower inpatient care
costs. The cost per life-year gained (LYG) amounted to $64,616.CONCLUSIONS:The
study suggests that mRCC survival has improved in recent years while costs have
increased, resulting in a fairly modest cost per LYG in a Swedish setting.
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